GNOM Global X Fds Genomics & Biotechnology Etf
- 10.170
- -0.190-1.83%
Intellia Therapeutics Analyst Ratings
Qiagen Analyst Ratings
CRISPR Therapeutics Analyst Ratings
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Raises Price Target to $45
Moderna Analyst Ratings
Oppenheimer Raises Price Target on Moderna to $179 From $163
Arrowhead Pharma Analyst Ratings
Avidity Biosciences Analyst Ratings
Jefferies Adjusts Price Target on Moderna to $180 From $155, Keeps Buy Rating
Arrowhead Pharma Analyst Ratings
Intellia Therapeutics Analyst Ratings
Natera Analyst Ratings
Moderna Analyst Ratings
Arrowhead Pharma Analyst Ratings
Myriad Genetics Analyst Ratings
Moderna Analyst Ratings
JMP Securities Remains a Hold on Intellia Therapeutics (NTLA)
RBC Raises Moderna's Price Target to $160 From $135
Arrowhead Pharmaceuticals (ARWR) Gets a Buy From RBC Capital